A New Treatment Option for Uncommon EGFR Mutations (BMIC-023)
Dr. Jack West reviews the new FDA approval for afatinib (Gilotrif) for specific uncommon EGFR mutations, including G719X, L861Q, and S768I, in advanced NSCLC. (6:35)
Beacon Medical Interchange – BeaconMedIC
Timely commentary on healthcare in general, cancer in particular.
